Timing of Conversion to Mammalian Target of Rapamycin Inhibitors Is Crucial in Liver Transplant Recipients With Impaired Renal Function at Transplantation
Authors:
- C. SchleicherCSC. Schleicher
- D. PalmesDPD. Palmes
- M. UtechMUM. Utech
- E. BonrathEBE. Bonrath
- N. SenningerNSN. Senninger
- H. SchmidtHSH. Schmidt
- H. WoltersHWH. Wolters
- 1 September 2010
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 42 (7) , 2572-2575
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trialLiver Transplantation, 2009
- Indications and Management of Everolimus After Liver TransplantationTransplantation Proceedings, 2009
- The Impact of Everolimus on Renal Function in Maintenance Liver TransplantationTransplantation Proceedings, 2009
- Safety, Tolerability, and Efficacy of Everolimus in De Novo Liver Transplant Recipients: 12- and 36-Month ResultsLiver Transplantation, 2006
- Sirolimus Conversion After Liver Transplantation: Improvement in Measured Glomerular Filtration Rate After 2 YearsTransplantation Proceedings, 2005
- Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimusLiver Transplantation, 2003
- Chronic Renal Failure after Transplantation of a Nonrenal OrganNew England Journal of Medicine, 2003
- Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipientsLiver Transplantation, 2003
- Calcineurin inhibitor‐induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agentClinical Transplantation, 2002
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976